While bisphosphonates reduce fracture risk over 3 to 5 years, the optimal duration of treatment is uncertain. In a randomized extension study (E1) of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT), zoledronic acid (ZOL) 5 mg annually for 6 years showed maintenance of bone mineral density (BMD), decrease in morphometric vertebral f...

Oral bisphosphonates are of proven efficacy in preventing fractures in postmenopausal osteoporosis. However, poor adherence limits their real-world efficacy and clinical utility. Zoledronic acid (ZOL) is a potent bisphosphonate administered by annual intravenous infusion, effectively ensuring adherence to therapy over the following year. According to available data, 66% to 79% of patients have ...

The interaction between two Fusarium mycotoxins, zearalenone (ZEN) and its derivative (')alpha-zearalenol ((')alpha-ZOL), with two food-grade strains of Lactobacillus was investigated. The mycotoxins (2 microg ml(-1)) were incubated with either Lactobacillus rhamnosus strain GG or L. rhamnosus strain LC705. A considerable proportion (38 to 46%) of both toxins was recovered from the bacterial pe...

Mesenchymal stem cells (MSCs) undergo a decline in function following ex vivo expansion and exposure to irradiation. This has been associated with accumulation of DNA damage and has important implications for tissue engineering approaches or in patients receiving radiotherapy. Therefore, interventions, which limit accumulation of DNA damage in MSC, are of clinical significance. We were intrigue...

Zoledronic acid (Zol) is the most potent inhibitor of bone resorption among the bisphosphonates and is commonly used for inhibiting bone metastasis. However, it remains unclear whether Zol provides a survival benefit. Recent findings indicate that epidermal growth factor (EGF) signaling is an important mediator of bone metastasis. Thus, we examined the combined effects of Zol and an EGF recepto...

Objective: To test the hypothesis that zoledronic acid will inhibit tumor-induced osteolysis and reduce tumor growth and invasion in a xenograft mouse model of bone invasive oral squamous cell carcinoma (OSCC). In humans, OSCC is the 6th most common cancer in the world. Bone invasion frequently occurs and is associated with poor prognosis and reduced survival. OSCC is the most commonly diagnose...

nitrogen-containing bisphosphonates (BiS) are potent inhibitors of bone resorption and are used in the treatment of a number of medical conditions, including multiple myeloma, breast cancer and osteoporosis. recent experimental evidence demonstrates that BiS also affect endothelial cell functions and angiogenesis; however, the molecular mechanism(s) are unclear. Vascular endothelial growth fact...

The title compound, [CuBr(C(9)H(9)N(5))](n), prepared by the solvothermal treatment of CuBr with 4-(2-allyl-2H-tetra-zol-5-yl)pyridine, is a new homometallic Cu(I)-olefin coordination polymer in which dinuclear Cu(2)Br(2) units are linked by the organic olefin ligand 4-(2-allyl-2H-tetra-zol-5-yl)pyridine, which acts as a bidentate ligand connecting two neighbouring Cu(2)Br(2) units through the ...

The title compound, [Zn(C(8)H(6)N(5)O(2))(2)(H(2)O)(2)], was synthesized by hydro-thermal reaction of ZnBr(2) with 2-[5-(2-pyrid-yl)-2H-tetra-zol-2-yl]acetic acid. The Zn(II) atom lies on an inversion center in a distorted octa-hedral environment with two planar trans-related N,N'-chelating 2-[5-(2-pyrid-yl)-2H-tetra-zol-2-yl]acetic acid ligands in the equatorial plane and two water mol-ecules ...

Background/Aim: A temporary influenza-like condition, called acute-phase reaction (APR), is commonly observed with intravenous (IV) administration of nitrogen-containing amino bisphosphonates, such as zoledronic acid (ZOL). This single-center study aimed to evaluate the incidence APR symptoms after ZOL in patients postmenopausal osteoporosis who were admitted emergency department (ED).
 Me...